BROOMFIELD, Colo. - Aclarion, Inc. (NASDAQ:ACON, ACONW), a healthcare technology company, announced today it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent ...

In a challenging year for Aclarion, the medical technology company's stock has plummeted to a 52-week low, trading at $4.41. According to InvestingPro data, the company maintains a healthy liquidity ...

The trial aims to validate Nociscan’s ability to improve surgical outcomes for chronic low back pain patients. Enrolling 300 patients across multiple sites, it builds on peer-reviewed data ...

Dr. Sigurd Berven to Highlight NOCISCAN Capabilities, Combining MR Spectroscopy and Augmented Intelligence (AI) NOCISCAN as New Gold Standard in ...

Northwestern Medicine is a global leader in clinical trial research, including spineCLARITY is a randomized study designed to demonstrate ...

Aclarion, Inc. has announced that Northwestern Medicine will serve as the initial site for its pivotal clinical trial, CLARITY, designed to assess the effectiveness and economic value of Nociscan ...

Aclarion stock is trading higher on Tuesday after the company announced it secured funding for its CLARITY trial of its ...

Aclarion, Inc. (NASDAQ: ACON) shares cleared breakeven Tuesday, as the health-care technology company announced it has received a Notice of Allowance from the United States Patent and Trademark Office ...

Aclarion, Inc. has successfully secured nearly $20 million in gross proceeds to fund its pivotal CLARITY trial, aimed at validating the Nociscan platform's effectiveness in improving surgical ...

Renowned spine specialist, Dr. Sigurd Berven, will present Aclarion's flagship platform, NOCISCAN, highlighting its innovative, evidence-supported capabilities. “Aclarion is pleased to have ...

CLARITY is a randomized study designed to demonstrate Nociscan’s ability to improve surgical outcomes while reducing costs for chronic low back pain Nociscan aims to become the gold standard in ...